Ascendis Pharma A/S (ASND) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$228.48

From 52W high−17.04%

Volume1.27M

Market cap$15.13B

P/E (TTM)16.9x

P/S (TTM)12.8x

Div yield—

Key dataOct 19, 2026

Open

$228.48

From 52W high

−17.04%

Volume

1.27M

Market cap

$15.13B

ValuationView details →

P/E (Fwd)

27.5x

EV/EBITDA

168.0x

P/E (TTM)

16.9x

RSI (14)

46.4

MomentumView details →

1D Return

+2.09%

YTD Return

+7.73%

SummaryUpdated Jun 1, 2026

Ascendis Pharma A/S (NASDAQ:ASND) is a Danish biopharmaceutical company founded in 2006 and headquartered in Hellerup, Denmark. The company went public on NASDAQ in January 2015. Ascendis specializes in developing innovative therapeutics for rare endocrine diseases using its proprietary TransCon technology platform, which enables the creation of long-acting versions of existing drugs. The company has successfully commercialized two products and maintains a robust pipeline of treatments targeting unmet medical needs in endocrinology and oncology.

Ask drillr about Ascendis Pharma A/S →

ValuationView details →

P/E (Fwd)

27.5x

P/E (TTM)

16.9x

EV/EBITDA

168.0x

EV/Sales

12.4x

P/S (TTM)

12.8x

P/B (TTM)

9.4x

ProfitabilityView details →

Gross Margin

90.19%

Net Margin

71.69%

EBITDA Margin

7.41%

ROE (TTM)

52.64%

ROA (TTM)

33.08%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+114.85%

EPS YoY

+365.93%

FCF YoY

+297.19%

Revenue CAGR 3Y

+138.21%

EPS CAGR 3Y

+44.56%

EBITDA YoY

+151.76%

MomentumView details →

1D Return

+2.09%

YTD Return

+7.73%

1Y Return

+11.95%

RSI (14)

46.4

vs 50D SMA

−5.71%

vs 200D SMA

−2.90%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.99x

Quick Ratio

2.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.29

EPS Surprise

117.88%

Beats (12Q)

7/12

Next Q EPS Est

$1.20

Avg Surprise (4Q)

−245.44%

Rev Surprise

1.18%

Financials snapshotView financials →

Revenue (TTM)

1.05B

Net Income (TTM)

755.85M

Op. CF (TTM)

351.32M

Next earningsNov 11, 2026 →

Latest newsMore news →

BioMarin Pharmaceutical granted Ascendis Pharma a non-exclusive worldwide license to certain patents for products including TransCon CNP, navepegritide, and Yuviwel, with Ascendis paying 20% royalties on US net sales and 18% in the EU, Brazil, and South Korea until May 2030, and the parties agreed to dismiss all pending litigation with prejudice.19d ago

Similar companies

Xcell Therapeutics, Inc.373110.KQ Exelixis, Inc.EXEL Metis Techbio-p07666.HK Halozyme Therapeutics, Inc.HALO Shanghai Junshi Biosciences Co., Ltd.01877.HK 生物股份600201.SH Find similar companies →

Latest newsMore news →

Ascendis Pharma announced that advances in its hypoparathyroidism and achondroplasia programs, including 5-year combined skeletal data for TransCon PTH (palopegteriparatide), will be presented at ASBMR 2026 in Boston on October 9-12, 2026.14d ago BioMarin Pharmaceutical granted Ascendis Pharma a non-exclusive worldwide license to certain patents for products including TransCon CNP, navepegritide, and Yuviwel, with Ascendis paying 20% royalties on US net sales and 18% in the EU, Brazil, and South Korea until May 2030, and the parties agreed to dismiss all pending litigation with prejudice.19d ago Ascendis Pharma will regain all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, and plans to initiate multiple programs in those areas including obesity.35d ago